



12th February 2026

Stock Code BSE: 500696

NSE: HINDUNILVR

ISIN: INE030A01027

BSE Limited,  
Corporate Relationship Department,  
2nd Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street,  
Mumbai – 400 001

National Stock Exchange of India Ltd  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra – Kurla Complex,  
Bandra (E),  
Mumbai – 400 051

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

The Company had informed:

- (a) Vide letter dated 4th January, 2023, acquisition of 19.8% shareholding of Nutritionalab Private Limited (Nutritionalab) and;
- (b) Vide letter dated 11th January, 2023, the proposed acquisition of shareholding in Zywie Ventures Private Limited (Zywie) as per the terms outlined in the Share Subscription and Share Purchase Agreement dated 8th December, 2022 and other documents executed pursuant thereto (SSSPA).

Pursuant to the provisions of Regulation 30 read with sub-para 1, Para A, Part A, Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (Listing Regulations), it is now informed that the Board of Directors of the Company, at its meeting held today i.e. 12th February 2026, has approved the following:

- (a) Acquisition of the balance stake of 49% in Zywie for cash consideration of INR 824 Crores (Indian Rupees Eight Hundred Twenty Four Crores), in accordance with the terms and conditions of the SSSPA ;
- (b) the sale of Company's entire 19.8% shareholding in Nutritionalab.

Consequent to the above acquisition of balance shareholding in Zywie, Zywie (and its wholly owned subsidiary Zenherb Labs Private Limited) shall become wholly owned subsidiaries of the Company.

Hindustan Unilever Limited,  
Unilever House,  
B D Sawant Marg, Chakala,  
Andheri East, Mumbai 400 099

Tel: +91 (22) 50433000 | Web: www.hul.co.in | CIN: L15140MH1933PLC002030



Hindustan Unilever Limited

The Transactions are subject to fulfilment of completion terms and conditions as specified in the respective Transaction Documents.

The Board Meeting commenced at 08.30 A.M. (IST) and the discussion on the above item concluded at 09.42 A.M. (IST). The Board Meeting is continuing for consideration of other agenda items.

The other information as required to be disclosed under aforesaid Regulation 30 of the Listing Regulations read with the relevant Circular(s) issued thereunder, is enclosed as **Annexure 1 & 2, respectively**.

A copy of the Press Release in this regard is also enclosed herewith as **Annexure 3**.

You are requested to take above information on record.

Thanking You.

Yours faithfully,

**For Hindustan Unilever Limited**

**Radhika**

**Kartik Shah**

Digitally signed by Radhika Kartik  
Shah  
Date: 2026.02.12 10:07:22 +05'30'

**Radhika Shah**

**Company Secretary & Compliance Officer**

**Membership No: A19308**



**ANNEXURE 1**

**Disclosure under sub-para (1) of Para (A) of Part (A) to Schedule III of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sr. No	Particulars	Description
1.	<b>Name of the target entity, details in brief such as size, turnover etc.</b>	Zywie Ventures Private Limited (" <b>Target</b> "), a private limited company incorporated in India, with a turnover from operations of INR 257.67 Crores for the financial year 2024-2025.  Indirect acquisition of Zenherb Labs Private Limited (" <b>Subsidiary</b> "), incorporated as a private limited company in India with turnover from operations of INR 37.26 Lacs for the financial year 2024-2025.
2.	<b>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"</b>	Yes. The Target is an existing Subsidiary of the Company.  The promoter/ promoter group/group companies have no interest in the Target and the Subsidiary.  The transaction is being undertaken on an arms' length basis.
3.	<b>Industry to which the entity being acquired belongs</b>	Health & Wellbeing (Vitamins, Minerals and Supplements) and Beauty and Personal Care.
4.	<b>Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)</b>	Acquisition of the remaining 49% of the shareholding in the Target, such that the Target and indirectly the Subsidiary, become wholly owned subsidiaries of the Company.
5.	<b>Brief details of any governmental or regulatory</b>	None.



	<b>approvals required for the acquisition</b>									
6.	<b>Indicative time period for completion of the acquisition</b>	Subject to fulfilment of terms and conditions as under the definitive documents, the completion is expected to occur by 31st March, 2026, subject to any extension as per the terms of definitive documents								
7.	<b>Consideration - whether cash consideration or share swap or any other form and details of the same</b>	Cash consideration								
8.	<b>Cost of acquisition and/or the price at which the shares are acquired</b>	Cash consideration of INR 824 crores to Sellers.								
9.	<b>Percentage of shareholding / control acquired and / or number of shares acquired</b>	Company shall acquire the balance 49.00% shareholding of the Target thereby acquiring 100% of the shareholding of the Target (and indirectly of the Subsidiary).								
10.	<b>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)</b>	<p>The Target was incorporated on 13th August, 2013, under the provisions of the Companies Act, 1956.</p> <p>The Target is involved in manufacturing, selling, trading and dealing in <i>inter alia</i>: (a) Vitamins, Minerals and Supplements; (b) Beauty and Personal Care and (c) Protein products;</p> <p>The Target primarily sells its products in India.</p> <p>The turnover from operations of the Target for the last three years is as follows:</p> <table border="1"> <thead> <tr> <th><b>Year</b></th> <th><b>Turnover (INR Crores)</b></th> </tr> </thead> <tbody> <tr> <td>FY 2024-25</td> <td>257.67</td> </tr> <tr> <td>FY 2023-24</td> <td>103.72</td> </tr> <tr> <td>FY 2022-23</td> <td>100.07</td> </tr> </tbody> </table>	<b>Year</b>	<b>Turnover (INR Crores)</b>	FY 2024-25	257.67	FY 2023-24	103.72	FY 2022-23	100.07
<b>Year</b>	<b>Turnover (INR Crores)</b>									
FY 2024-25	257.67									
FY 2023-24	103.72									
FY 2022-23	100.07									



**ANNEXURE 2**

**Disclosure under sub-para (1) of Para (A) of Part (A) to Schedule III of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

S. No.	Particulars	Description
1.	<b>The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;</b>	The revenue from operations of Nutritionalab Private Limited (" <b>Nutritionalab</b> ") for the financial year 2024-25 is INR 118.48 crores. Nutritionalab is classified as Joint venture and is accounted using 'Equity method' in consolidated financial statements under Ind AS. Under equity method of accounting, the revenue of Nutritionalab is not recognized in HUL's consolidated results.
2.	<b>Date on which the agreement for sale has been entered into;</b>	12th February 2026
3.	<b>The expected date of completion of sale/disposal;</b>	Subject to fulfilment of terms and conditions as under the Transaction Documents, the completion of the transaction is expected by 31st March 2026, subject to any extension as per terms of the Transaction Documents.
4.	<b>Consideration received from such sale/disposal;</b>	INR 307 crores, subject to customary closing adjustments
5.	<b>Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;</b>	USV Private Limited is the buyer entity involved in the transaction. The buyer does not belong to promoter/promoter group/ group companies of HUL in any manner.
6.	<b>Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";</b>	The Transaction does not fall within related party transactions.
7.	<b>Whether the sale, lease or disposal of the undertaking is outside the Scheme of</b>	The proposed transaction does not form part of any Scheme of Arrangement. Accordingly, the provisions of Regulation

Hindustan Unilever Limited,  
Unilever House,  
B D Sawant Marg, Chakala,  
Andheri East, Mumbai 400 099

Tel: +91 (22) 50433000 | Web: www.hul.co.in | CIN: L15140MH1933PLC002030



Hindustan Unilever Limited

S. No.	Particulars	Description
	<b>Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations</b>	37A of LODR Regulations are not applicable in the present case.
8.	<b>Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.</b>	Not Applicable



Hindustan Unilever Limited

PRESS RELEASE

**HUL invests Rs. 824 crores to acquire remaining 49% stake in Zywie Ventures (OZiva)  
Divests 19.8% holding in Nutritionalab**

**Mumbai, 12 February 2026:** Hindustan Unilever Limited (HUL) today announced two strategic moves in its Health & Wellbeing (H&W) business - the full acquisition of Zywie Ventures Private Limited ("OZiva") and the divestment of its minority stake of 19.8% in Nutritionalab Private Limited, for a consideration of Rs. 824 crores and Rs. 307 crores, respectively.

Since entering the H&W category in 2023, HUL has focused on building a strong presence in this nascent yet fast-growing consumer space. OZiva has delivered strong performance following HUL's majority investment of 51% — scaling to approximately Rs. 480 crores in 2025 with a growth of c. 130% CAGR in last 2 years by developing a winning portfolio and unlocking significant synergies through HUL's ecosystem. The Board of Directors of HUL has approved the acquisition of the remaining 49% stake as per the pre-agreed valuation framework, for a consideration of Rs. 824 crores, making OZiva a wholly owned subsidiary of the Company.

In line with its strategy of continued portfolio transformation through fewer, bigger bets, HUL's Board has approved the sale of its minority stake of 19.8% in Nutritionalab Private Limited to USV Private Limited for a consideration of Rs. 307 crores.

Both transactions are expected to close by March 2026, subject to customary closing conditions.

**Priya Nair, CEO and Managing Director, HUL,** said: *"Health & Wellbeing is an important growth vector for us, driven by rising consumer interest in everyday wellness. By taking full ownership of OZiva, we are doubling down on this exciting space to unlock the next phase of growth. Our decisions today reflect our intent of fewer, bigger bets where we can leverage HUL's strengths in science, distribution and market development to scale purpose-led brands."*

+++

**About Hindustan Unilever Limited (HUL)**

Hindustan Unilever Limited (HUL) is India's largest Fast-Moving Consumer Goods company, with its products touching the lives of nine out of ten households in the country. HUL works to create a better future every day.

**Media enquiries:** [Mediacentre.hul@unilever.com](mailto:Mediacentre.hul@unilever.com)